QLT Looks Beyond Ophthalmology To Treat Skin Cancer With Visudyne
This article was originally published in The Gray Sheet
Executive Summary
QLT expects to complete enrollment of its pivotal Visudyne trial for multiple basal cell carcinoma by year-end and envisions U.S. approval in 2005